September 21, 2020 Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study
September 21, 2020 GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)
September 18, 2020 Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 16, 2020 Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
September 15, 2020 GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
September 09, 2020 Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options